These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. Daley MF; Clarke CL; Glanz JM; Xu S; Hambidge SJ; Donahue JG; Nordin JD; Klein NP; Jacobsen SJ; Naleway AL; Jackson ML; Lee G; Duffy J; Weintraub E Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):59-68. PubMed ID: 29148124 [TBL] [Abstract][Full Text] [Related]
4. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019. Moro PL; Woo EJ; Marquez P; Cano M Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434 [TBL] [Abstract][Full Text] [Related]
5. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). Niu MT; Rhodes P; Salive M; Lively T; Davis DM; Black S; Shinefield H; Chen RT; Ellenberg SS J Clin Epidemiol; 1998 Jun; 51(6):503-10. PubMed ID: 9635999 [TBL] [Abstract][Full Text] [Related]
6. Risk of anaphylaxis after vaccination in children and adults. McNeil MM; Weintraub ES; Duffy J; Sukumaran L; Jacobsen SJ; Klein NP; Hambidge SJ; Lee GM; Jackson LA; Irving SA; King JP; Kharbanda EO; Bednarczyk RA; DeStefano F J Allergy Clin Immunol; 2016 Mar; 137(3):868-78. PubMed ID: 26452420 [TBL] [Abstract][Full Text] [Related]
7. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018. Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795 [TBL] [Abstract][Full Text] [Related]
9. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511 [TBL] [Abstract][Full Text] [Related]
10. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System. Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076 [TBL] [Abstract][Full Text] [Related]
11. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. Su JR; Moro PL; Ng CS; Lewis PW; Said MA; Cano MV J Allergy Clin Immunol; 2019 Apr; 143(4):1465-1473. PubMed ID: 30654049 [TBL] [Abstract][Full Text] [Related]
12. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Wattigney WA; Mootrey GT; Braun MM; Chen RT Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733 [TBL] [Abstract][Full Text] [Related]
13. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128 [TBL] [Abstract][Full Text] [Related]
14. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. ; MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297 [TBL] [Abstract][Full Text] [Related]
15. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010. Moro PL; Arana J; Cano M; Menschik D; Yue X; Lewis P; Haber P; Martin D; Broder K Clin Infect Dis; 2012 Jun; 54(11):1608-14. PubMed ID: 22441652 [TBL] [Abstract][Full Text] [Related]
16. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194 [TBL] [Abstract][Full Text] [Related]
17. Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink. Yih WK; Duffy J; Su JR; Bazel S; Fireman B; Hurley L; Maro JC; Marquez P; Moro P; Nair N; Nelson J; Smith N; Sundaram M; Vasquez-Benitez G; Weintraub E; Xu S; Shimabukuro T Am J Otolaryngol; 2024; 45(6):104448. PubMed ID: 39096568 [TBL] [Abstract][Full Text] [Related]
18. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System. Woo EJ; Moro PL; Cano M; Jankosky C Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946 [TBL] [Abstract][Full Text] [Related]
19. Allergic reactions to Japanese encephalitis vaccine. Plesner AM Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386 [TBL] [Abstract][Full Text] [Related]
20. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]